Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Stopped After the analysis of the main ADORE study it is concluded that there is no clinical benefit for the patients.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
Sponsor
Ferrer Internacional S.A.